Adial Pharmaceuticals
Adial Pharmaceuticals develops prescription medications for addiction and related disorders.
About Adial Pharmaceuticals
Adial Pharmaceuticals engages in the development of prescription medications for addiction and related disorders in the United States. The company's research pipeline includes AD04, a compound that completed the Phase IIb study for the treatment of alcohol use disorders; and AD01, which completed the Phase I clinical-stage for treating addictive behaviors.
Company Facts
- Headquarters
- Charlottesville
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- public
- Employees
- c_00011_00050
- Funding Stage
- ipo
- Total Funding
- $40,674,042
- Last Funding Type
- post_ipo_equity
- Last Funding Date
- 2025-06-17
- Website
- adialpharma.com
Industries & Categories
Addiction Treatment, Biotechnology, Health Care, Pharmaceutical
Social Links
Canonical: https://fsome.com/organization/adial-pharmaceuticals-141412 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.